To study side effects and benefits of tablet Palbociclib in metastatic breast cancer patients within period of January 2016 till December 2018.
Not Applicable
Completed
- Conditions
- Health Condition 1: C50- Malignant neoplasm of breast
- Registration Number
- CTRI/2020/05/025231
- Lead Sponsor
- Tata Memorial Centre
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 101
Inclusion Criteria
i.Patients with histopathologically confirmed ER/PR positive and HER- 2 negative metastatic breast cancer.
ii.Patients who have been started on palbociclib with atleast one record of treatment with palbociclib from the year January 2016 till December 2018 will be included in study. Data will be obtained from the electronic medical records from our hospital
Exclusion Criteria
i.Patients having HER- 2 positive metastatic breast cancer.
ii.Patients receiving Palbacoclib or Ribocliclib under any industry sponsored trials
iii.Patientâ??s on palbociclib but not having details on EMR
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary objectives of the study includes study of efficacy of palbociclib including progression free survival and overall survival.Timepoint: January 2016 till December 2018.
- Secondary Outcome Measures
Name Time Method The secondary objectives include the analysis of toxicities including incidence of grade 3 or 4 neutropenia, anemia and diarrheaTimepoint: January 2016 till December 2018.